TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01974115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
Study: NCT00806234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole or Perphenazine
Description: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Description: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
Study: NCT00006364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Description: Given IV or SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01331460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBT
Description: Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case-Management
Description: Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs
Study: NCT02417103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 (Liraglutide)
Description: GLP-1 Analogon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03610763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Constraint Induced Movement Therapy
Description: In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Constraint Induced Movement Therapy
Description: In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
Study: NCT00209807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 10 mg/d for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reboxetine
Description: Reboxetine 8 mg/d for 6 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: This group of healthy volonteers will receive no drug and will be a healthy comparator.
Study: NCT03178279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Health Plan
Description: Use of a Physical Health Plan by service users
Study: NCT01313143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOP200704
Description: Comparison of AOP200704 with Esmolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol hydrochloride, infusion
Description: Comparison of AOP200704 with Esmolol
Study: NCT00089089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01343602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mod. Constraint-Induced Movement Therapy
Description: Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training.

Intervention type: OTHER
Group type: OTHER
Intervention: Therapy as usual
Description: Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
Study: NCT04436263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplement
Description: A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
Study: NCT04585659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
Study: NCT04080752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 will be administrated orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study: NCT03219385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirabilis System
Description: The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
Study: NCT01906684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
Study: NCT02026180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropuncture Access
Description: Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropuncture Access
Description: Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
Study: NCT03486028

Intervention type: OTHER
Intervention: Adherence to ASAM protocols
Description: ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.

Intervention type: OTHER
Intervention: Adherence to ASAM protocols
Description: ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.

Intervention type: OTHER
Intervention: Non-adherence to ASAM protocols
Description: These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
Study: NCT02607982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
Study: NCT04105335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous administration
Study: NCT04224064

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
Study: NCT03354364

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pea hull fiber
Description: Snacks containing 15 g/day of ground pea hulls.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pea hull fiber
Description: Snacks containing 15 g/day of ground pea hulls.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Snacks without added fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Snacks without added fiber.
Study: NCT03933475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality game
Description: Use of virtual reality games on television screens
Study: NCT04569110

Intervention type: OTHER
Intervention: Not applicable. Observational study. Retrospective analysis of samples.
Description: Not applicable. Observational study. Retrospective analysis of samples.

Intervention type: OTHER
Intervention: Not applicable. Observational study. Retrospective analysis of samples.
Description: Not applicable. Observational study. Retrospective analysis of samples.
Study: NCT03362463

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT03261102

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study: NCT02733809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
Study: NCT04056884

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIBS intervention
Description: SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
Study: NCT02103621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taper and Monitoring (TAP-M)
Study: NCT02609880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
Study: NCT03147235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vitrectomy with music listening
Description: Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
Study: NCT04000867

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Magnetic Stimulation (TCMS)
Description: The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Magnetic Stimulation (TCMS)
Description: The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
Study: NCT04876794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
Study: NCT01599390

Intervention type: OTHER
Intervention: Data collection
Description: The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted.
Study: NCT00403897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 Na bicarbonate NaCl KCl
Description: 6.9g sachet, oral
Study: NCT04378322

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and food purchasing tool + telenutrition
Description: Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and food purchasing tool
Description: Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education tool
Description: Participants will be asked to review nutrition education materials online.
Study: NCT01360541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation
Description: HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surveillance
Description: Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
Study: NCT02331797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Technique
Description: Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microscopic Technique
Description: Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
Study: NCT03115294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: iv injection
Study: NCT03486158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CalproSmart™ system
Description: Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
Study: NCT00835224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NAME
Description: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: To treat low blood pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill with an inactive substance that looks like the study drug.
Study: NCT00803790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium+vitamin D combination
Description: A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium+vitamin D combination
Description: A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium+vitamin D combination
Description: A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
Study: NCT03115294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilator positive end expiratory pressure adjustment
Description: Positive end-expiratory pressure variation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videorecording
Description: Myocardial movement videorecording
Study: NCT01000623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Given orally